People
OSR Health, an Open and Socially Responsible Healthcare Group
Board of Directors - Independent
Seng Chin Mah, PhD
Seng Chin Mah, PhD
✦ | Chairman, BioVersys AG |
✦ | CEO, Canyon Pharmaceuticals Group AG |
✦ | Executive positions, Novartis |
Alcide Barberis, PhD
Alcide Barberis, PhD
✦ | CEO, Mabylon AG |
✦ | CEO, Humabs Biomed |
✦ | Co-founder, ESBATech AG |
Joong Myung Cho, PhD
Joong Myung Cho, PhD
✦ | Founder, Chairman and CEO, CrystalGenomics, Inc. |
✦ | Founder, Chairman and CEO, CG Pharmaceuticals, Inc. |
✦ | Executive Senior Managing Director & Director of R&D, LG Chem Biotech Research Institute |
✦ | Ph.D., University of Houston |
✦ | M.S. & B.S., Seoul National University |
Hyuk Joo Jee
Hyuk Joo Jee
✦ | Special Advisor, DongKoo Bio Pharma Co., Ltd. |
✦ | COO and Head of Corporate PE, HLB Co., Ltd. |
✦ | Korea Investment Securities (London) |
Reto Fierz
Reto Fierz
✦ | Co-founder and Partner of digital asset advisory group, DAVG GmbH |
✦ | CFO, Swiss Finance & Property Corp. |
✦ | Consultant to World Bank assisting governments in Central Asia. |
✦ | Expert in IFRS; Chartered Account in Switzerland; MSc Economics. |
Team
Peter Hwang 황국현
Chief Executive Officer
Chairman of the Board of Directors
Peter Hwang 황국현
Chief Executive Officer
Chairman of the Board of Directors
| Founder/Managing Partner, Bellevue Capital Management, LLC |
| Korea Representative, Bellevue Asset Management AG |
| Strategic Planning, International Business Development, Shinhan Investment Corp. |
| B.A. in Sociology, Korea University |
Chris Bang 방기현
Chief Financial Officer
Chris Bang 방기현
Chief Financial Officer
| Vice President, Corporate Private Equity Team, COO, Newlake Alliance Management |
| Equity Capital Market Team Head, IPO Department, Risk Management Department, Shinhan Investment Corp. |
| B.A. in International Trade, Hansung University |
Tim Smith
Corporate Secretary, Global IR
Tim Smith
Corporate Secretary, Global IR
| Equity Sales Trader, HSBC Securities Seoul |
| Equity Sales Trader, Shinhan Investment Corp |
| Equity Derivatives Trader, Morgan Stanley Seoul |
| B.A. in Computer Science with Korean language, University of Newcastle |
Senyon "Teddy" Choe, PhD
Founder/Chief Executive Officer, Darnatein
Senyon "Teddy" Choe, PhD
Founder/Chief Executive Officer, Darnatein
| Founder, Darnatein |
| Founder, Joint Center for Bioscience(JCB) |
| Ph.D, Biophysics and Medical Physics, University of California, Berkeley |
| B.S. in Biological Sciences, Seoul National University |
Constance Höfer, PhD
Chief Scientific Officer, OSR Holdings
Constance Höfer, PhD
Chief Scientific Officer, OSR Holdings
| Global Program Head, Merck Healthcare |
| Global Progam Head, Sandoz Biopharma |
| COO, Priaxon AG |
| VP Drug Development, medigene AG |
| Ph.D, Pharmacology, University of Newcastle |
ChanKyu Park
Chief Executive Officer, RMC
ChanKyu Park
Chief Executive Officer, RMC
✦ | Hutem |
✦ | MicroVention |
✦ | Boston Scientific Korea |
✦ | Janssen Korea |
Jun Chul Whang, JD
Chief Legal Officer and Director
Jun Chul Whang, JD
Chief Legal Officer and Director
✦ | Partner and General Counsel, Bellevue Capital Management, LLC |
✦ | Partner, Greenspoon Marder (NYC) |
✦ | Partner, Jacob Medinger & Finnegan (NYC) |
✦ | B.A., Dartmouth College |
✦ | J.D., Cornell Law School |
✦ | LL.M., Georgetown University Law Center |
Daeho Kim
Internal Auditor
Daeho Kim
Internal Auditor
✦ | Founder, Stonemountain Advisor, LLC |
✦ | Managing Partner, North Head Capital Partners, LLC |
✦ | Director, Alliance Capital Partners Co., Ltd ("ACPC") |
✦ | VP, SsangYong Investment & Securities |
✦ | M.A. in Accounting, University of Denver |
Josh Pan, PhD
Venture Partner
Josh Pan, PhD
Venture Partner
| Partner, Bellevue Capital Management, LLC |
| Chief Business Officer, Landmark BioVentures AG |
| Vice President Corporate Development and External Affairs, Athira Pharma |
| Chief Operating Officer, W Fund |
| Ph.D. Molecular and Cellular Biology, University of Washington |
| MBA, University of Washington |
Jessi Kim
Senior Analyst
Jessi Kim
Senior Analyst
| M.D., Chonbuk National University School of Medicine |
| B.S. in Environmental Science, Seoul National University |
Taemin Lee
Analyst
Taemin Lee
Analyst
✦ | B.A. in Business Administration, University of Southern California |
Sein Yang
Analyst
Sein Yang
Analyst
| B.S. in Computer Science and Engineering, Chonnam National University |
Frequently Asked Questions
All shareholders who own OSR Health common stock as of the applicable Record Date are eligible to apply for the Shareholder Loyalty CVR Program. Shareholders must complete the required enrollment process and satisfy the applicable program requirements before Contingent Value Rights (CVRs) are issued.
Enrollment is completed by submitting the appropriate application form. U.S. shareholders will need to hold their shares through Direct Registration (DRS) with the Company's transfer agent before enrolling. Non-U.S. shareholders enroll through a separate application process. Full instructions and forms are available on this page.
The Shareholder Loyalty CVR Program is designed to reward long-term ownership. If you sell, transfer, or otherwise dispose of the shares associated with your CVRs before the applicable milestone is achieved, those CVRs will generally terminate and will no longer be eligible to receive additional shares.
Extra shares recieved by reaching are milestones are free to be sold and don't affect future milestone rewards associated with the CVRs from the original shares held on record date.
Once your enrollment has been approved, no further action is generally required. Simply continue to hold your enrolled shares and remain eligible under the terms of the program. If applicable share price milestones are achieved during the program period, eligible U.S. shareholders will receive the corresponding share distributions in accordance with the program terms. Non U.S. shareholders will have to provide a broker attestation on each measurement date to confirm their original shares position.
*The Shareholder Loyalty Program is still subject to receipt of a legal opinion confirming the applicable securities law requirements have been complied with. The program remains subject to change and has not been finalized.
OSR Health, Inc. Reg No. 589-86-01485
Email: ir@osr-health.com
US: 10900 NE 4th Street, 2300 Bellevue, WA 98004
KR: B-dong, 3F, 37-36 Hoedong-gil, Paju-si, Gyeonggi-do
CH: Technologiepark Basel, Hochbergerstrasse 60c
Copyright © OSR Health, Inc. All Rights Reserved.